Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2008) 15 P95

1Aberdeen Royal Infirmary, Aberdeen, UK; 2Glasgow Cardiovascular Research Centre, Glasgow, UK; 3Ninewells Hospital, Dundee, UK; 4Victoria Infirmary, Glasgow, UK; 5Royal Infirmary of Edinburgh, Edinburgh, UK.

Aim: To assess whether adults in Scotland currently receiving growth hormone (GH) meet the NICE criteria for starting and continuing GH replacement.

Methods: We surveyed all endocrinologists in Scotland and identified the main centres using GH replacement. A cross-sectional case note review was carried out of all patients commenced on GH.

Results: About 208 patients (51% women; 24% professionals, 90% Caucasian) were identified, 69 of whom started GH therapy after publication of the NICE criteria in August 2003. Tumours in the sellar region were the main cause of GH deficiency. All patients had baseline pituitary testing and were on other pituitary hormone replacements (thyroxine, 83%; hydrocortisone, 78%; testosterone, 71% men; oestrogens, 46% women; DDAVP, 24%). Ninety percent of patients had a dynamic GH stimulation test and 88% had a peak GH level below the recommended threshold (9 mU/l). Fifty-three patients (77%) had an AGHDA score >11 documented before commencing GH post-NICE compared with 35 (25%) pre-NICE. Only 39 patients (18%) met the full NICE criteria for starting and continuing GH (pre-NICE, 11%; post-NICE, 35%).

Conclusion: Although the use of quality of life assessments has increased after the release of the NICE guidelines, most patients in Scotland on GH do not satisfy the full set of NICE criteria.

Article tools

My recent searches

No recent searches.